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Abstract : Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors such as afatinib are used for non-
small cell lung cancer (NSCLC) and show varying efficacy depending on EGFR gene mutation. Few studies have 
examined the relationship between EGFR gene mutations and the adverse events of afatinib in NSCLC. This 
retrospective study included 32 Japanese patients with NSCLC with EGFR gene mutation who were treated with 
afatinib between May 2014 and August 2018 at Kagawa University Hospital. Among the 32 Japanese patients with 
NSCLC treated with afatinib, 19 patients were positive for exon 19 deletion mutation (Del 19) and 13 patients 
were negative for Del 19. The incidence of grade ≥ 2 skin rash was slightly higher in patients positive for Del 19 
(42.1% vs. 7.7%, P = 0.050). No significant differences were detected in other adverse events between the two pa-
tient groups. Patients positive for Del 19 also showed significantly longer median progression-free survival (288 
vs. 84 days, P = 0.049). Our study indicates a higher incidence of skin rash associated with afatinib treatment in 
Japanese patients with NSCLC positive for Del 19 compared with patients without Del 19. The Del 19 positive 
patient group also showed better progression-free survival. J. Med. Invest. 68 : 125-128, February, 2021
Keywords : non-small cell lung cancer, skin rash, exon 19 deletion mutation, afatinib
INTRODUCTION
 
Epidermal growth factor receptor (EGFR)-tyrosine kinase 
inhibitors (TKIs), i.e., gefitinib, erlotinib, afatinib, osimertinib, 
and dacomitinib, are administered for non-small cell lung cancer 
(NSCLC) positive for EGFR gene mutations. EGFR gene muta-
tions in NSCLC are frequently detected in the intracellular tyro-
sine kinase domain. Exon 19 deletion (Del 19) and exon 21 point 
mutation (L858R) account for 44.8% and 39.8%, respectively 
(85% in total) (1, 2). Both mutations indicate high susceptibility 
to EGFR-TKIs. However, the therapeutic effects of EGFR-TKIs 
on NSCLCs vary depending on the EGFR gene mutation. For 
example, the LUX-Lung 3 / 6 study demonstrated that afatinib 
prolonged progression free-survival (PFS) in Del 19 patients (3).
Although the effects of afatinib as first-line treatment may 
not necessarily be compared with first-generation TKIs, a me-
ta-analysis revealed that afatinib was more effective as a sec-
ond-line treatment for advanced squamous cell carcinoma than 
erlotinib (4). However, afatinib treatment should be started at a 
low dose in Del 19 patients at risk of malnourishment, sarcope-
nia, and low body surface area because of the higher incidence of 
adverse events, such as skin rash, diarrhoea, and mucositis (5).
EGFR is widely expressed in normal skin tissues and cells, 
such as the epidermis, sebaceous glands, glands, eccrine glands, 
and dendritic cells, and plays an important role in the normal 
development and physiology of the epidermis. The epidermis 
mainly originates from keratinocytes, and keratinocyte differ-
entiation and migration to the skin surface are regulated by the 
EGFR signalling pathway. EGFR-TKIs have been associated 
with the development of numerous adverse events, such as skin 
rash, diarrhoea, and mucositis, through their effects on inhibit-
ing EGFR signal transduction (6).
Several studies have reported the relationships between the 
adverse events and therapeutic effects of anticancer drugs, such 
as skin rash due to erlotinib in NSCLC patients (7), hand-foot 
syndrome due to capecitabine in breast cancer patients (8), 
and hypertension and proteinuria due to bevacizumab in col-
orectal and breast cancer patients (9, 10). However, few reports 
have been published on the relationship between EGFR gene 
mutations and the adverse events of EGFR-TKIs in NSCLC. 
We previously reported that Del 19 patients were less likely to 
develop skin rash than L858R patients, although no significant 
difference was found on comparison of each drug (11). In one 
study in Japan, the therapeutic effects of afatinib were more 
significant with skin rash of grade 2 or higher at 1 week of 
treatment, although no significant difference was found because 
it was a small-scale study (12). In this study, we retrospectively 
investigated the relationship between EGFR gene mutations 
and the incidence of adverse events in NSCLC patients receiving 
afatinib.
PATIENTS AND METHODS
Data collection and assessment
We retrospectively analysed the electronic medical records of 
inpatients with NSCLC who started afatinib between May 2014 
and August 2018. We excluded patients who received afatinib 
beyond the standard dose. We collected data on genetic mutation 
type, age, gender, body surface area (BSA), performance status 
(PS), liver and renal function before administration, number 
of EGFR-TKIs used as prior treatment, and maximum grade 
of adverse events (skin rash, diarrhoea, stomatitis, and liver 
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dysfunction). Grades of adverse effects were assessed according 
to the Common Terminology Criteria for Adverse Events version 
4.0. Observation periods were up to 2 weeks from starting ther-
apy, and patients were divided into those with adverse events of 
grade 0–1 and those with adverse events of grade 2. 
Assessment of treatment effectiveness
The best antitumour responses during the treatment pe-
riod were assessed with response evaluations (complete 
response : CR, partial response : PR, stable disease : SD, pro-
gressive disease : PD) by physicians according to the Response 
Evaluation Criteria in Solid Tumors (RECIST). Between-group 
PFS comparisons were also performed.
Statistical analysis 
We used IBM® SPSS® Statistics 24.0 (IBM Corp., Armonk, 
NY, USA) for statistical analyses. Baseline patient characteris-
tics were analysed using the Mann–Whitney U test and Fisher’s 
exact test. We used Fisher’s exact test for between-group adverse 
events and antitumour effect comparisons, with P < 0.05 indi-
cating a significant difference. The Kaplan–Meier method was 
used in the PFS analysis and the log-rank test was employed for 
comparisons between groups, with P < 0.05 indicating a signifi-
cant difference.
Ethics statement
This study was approved by the Kagawa University Ethical 
Research Committee (2018-201) and was conducted in accor-
dance with the Declaration of Helsinki and Ethical Guidelines 
for Medical and Health Research involving Human Subjects by 
the Ministry of Education, Culture, Sports, Science and Technol-
ogy, and the Ministry of Health, Labour and Welfare of Japan. 
Japanese law does not require individual informed consent from 
participants in non-invasive observational trials such as this 
study. Therefore, we used our clinical research support centre 
website as an opt-out method rather than acquiring written or 
verbal informed consent from patients.
RESULTS
This study included 32 Japanese patients with NSCLC, in-
cluding 19 patients positive for Del 19 and 13 patients negative 
for Del 19. All patients were treated with afatinib at the stan-
dard dose. The patient characteristics in the Del 19 positive and 
negative groups are listed in Table 1. No significant difference 
was found in age, gender, BSA, PS, liver and renal function 
before administration, and number of EGFR-TKIs used as prior 
treatment between groups.  
In the comparison between the two groups for the incidence of 
grade ≥ 2 adverse events, skin rash was slightly higher in the Del 
19 group than in the non-Del 19 group, but the difference was not 
significant (P = 0.050) (Table 2). No significant difference was 
observed for the other grade ≥ 2 adverse events.
Comparison of the objective response and disease control 
rates between the groups is shown in Table 3. The Del 19 group 
had a higher response rate (CR+PR) and disease control rate 




positive (n = 19) negative (n = 13)
Age (years) 72 (48-84) 71 (42-80) 0.762
Gender (M / F) 5 / 14 6 / 7 0.283
BSA (m2) 1.49 (1.02-1.74) 1.49 (1.22-1.86) 0.623
PS 0 (0-3) 0 (0-4) 0.520
AST (U / L) 23 (14-58) 19 (13-32) 0.404
ALT (U / L) 13 (6-66) 13 (8-20) 0.850
T-Bil (mg / dL)a 0.5 (0.4-1.0) 0.5 (0.4-0.9) 1.000
LDH (U / L) 263 (186-907) 225 (185-573) 0.195
ALP (U / L)b 250 (94-2808) 300 (132-582) 0.258
Scr (mg / dL) 0.6 (0.40-0.98) 0.69 (0.44-1.07) 0.287
Ccr (ml / min)c 85.0 (44.8-154.7) 66.8 (47.7-134.8) 0.940




Previously treated with 
1 EGFR-TKI 6 3
Previously treated with 
2 EGFR-TKIs 0 2
Data are expressed as the median (range)
BSA, body surface area ; PS, performance status ; AST, aspartate aminotransferase ; ALT, alanine 
aminotransferase ; T-Bil, total bilirubin ; LDH, lactate dehydrogenase ; ALP, alkaline phospha-
tase ; Scr, serum creatinine ; Ccr, creatinine clearance ; eGFR, estimated glemerular filtration rate.
aMissing values for 3 patients.
bMissing value for 1 patient.
cCcr was estimated by Cockcroft-Gault equation. 
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and 0.552, respectively).
The comparison of PFS between the groups is shown in Figure 
1. The median PFS for patients with and without Del 19 was 288 
and 84 days, respectively. The median PFS was significantly 
longer in patients with Del 19 (P = 0.049).
 
DISCUSSION
This study compared the adverse events in NSCLC patients 
with and without Del 19 treated with afatinib. Our results sug-
gested a higher incidence of skin rash due to afatinib treatment 
in patients with Del 19 compared with patients without Del 19. 
The most common EGFR gene mutations found in daily clinical 
practice in NSCLC patients are Del 19 and L858R. Of the 32 
patients included in the study, 19 and 13 patients carried Del 19 
and L858R, respectively. To examine the association of EGFR 
gene mutation with adverse events in response to afatinib, grade 
2 or higher adverse events that prevented patient daily activities 
were set as the cut-off value. As no difference was found in the 
patient background between the Del 19 positive and negative 
groups, the difference in the incidence of skin rash may not be 
because of a relative overdose. Because there was no difference 
in BSA, renal and hepatic function between the two groups. 
However, no significant difference was noted in the other adverse 
events. This may be explained by the development of skin rash as 
early as at 2 weeks in the observation period or the involvement 
of different factors. The preventive use of moisturizers and skin 
care procedures for skin rash were similarly performed among 
all patients, as all patients received the same formulation and 
instructions at the first prescription. Patients with poor PS were 
also able to perform uniform skin care by nurses during the 
hospitalization. Notably, the overall incidence of skin rash in 
our study was approximately 30% compared with 41.9% in the 
LUX-Lung 3 global phase III clinical study. However, this study 
cannot be simply compared with the LUX-Lung 3 study due to 
the observation period of only 2 weeks, age group, and racial 
differences. That is 229 patients in the LUX-Lung 3 study, only 
54 were Japanese. Therefore, different methods of skin care and 
racial differences may explain the inconsistent results.
Previous studies have reported relationships between gene 
mutations and therapeutic effects. One report showed that 
treatment outcomes, i.e., PFS and response rates, in response to 
afatinib were generally more satisfactory in Del 19 patients (3).
Our study was limited in that it was a small-scale single-site 
study. In addition, the reason underlying the relatively high 
incidence of diarrhoea regardless of gene mutation is not clear. 
To address this issue, a larger-scale study should be conducted.
CONCLUSIONS
Our study suggests that the incidence of skin rash and ther-
apeutic effects of afatinib in NSCLC patients vary according to 
gene mutations. This finding suggests the ability to predict the 
risk of skin rash before the start of treatment and may be useful 
for patient treatment. Furthermore, skin care instructions will 
be more important for such patients because more significant 
therapeutic effects can be expected. Thus, our study should fa-
cilitate the reduction of patients who discontinue treatment for 
adverse events.
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Fig 1.　Comparison of progression free survival between groups.
Kaplan-Meier method was used for survival analysis.




positive (n = 19) negative (n = 13)
skin rash 8 (42.1%) 1 (7.7%) 0.050
diarrhea 7 (36.8%) 5 (38.5%) 1.000
mucositis 5 (26.3%) 1 (7.7%) 0.361
liver dysfunction 0 (0%) 1 (7.7%) 0.520
Table 3.　Objective Response Rate and Disease Control rate for 
Each Group
Response
Del 19 mutation 
positive group
 (n = 19)
Del 19 mutation 
negative group





CR 1 (5.3) 0 (0)
PR 10 (52.6) 5 (38.5)
SD 7 (36.8) 6 (46.2)
PD 1 (5.3) 2 (15.4)
Objective Response
 (CR+PR) 11 (57.9) 5 (38.5) 0.437
Disease Control
 (CR+PR+SD) 18 (94.7) 11 (84.6) 0.552
CR : complete response. PR : partial response. SD : stable dis-
ease. PD : progressive disease. 
Fisher’s exact test was used for comparisons.
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